Sumitomo Pharma takes license to CRISPR/Cas9 patent portfolio from ERS Genomics'
Date
4/26/2022 3:07:01 AM
(MENAFN- PR Newswire)
DUBLIN, April 26, 2022 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to confirm finalization of a license agreement with Sumitomo Pharma Co., Ltd. ('Sumitomo Pharma') granting Sumitomo Pharma non-exclusive access to the fundamental CRISPR/Cas9 intellectual property portfolio held by ERS.
ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Eighty-nine patents are held in over eighty countries, including 3 patents in Japan with broad coverage of the use of CRISPR/Cas9.
Eric Rhodes, CEO ERS Genomics (PRNewsfoto/ERS Genomics)
ERS CEO Eric Rhodes had the following statement: 'We have been working with Sumitomo Pharma's group for some time and are pleased to finally be able to announce this agreement. Sumitomo Pharma has a reputation worldwide for excellence and vision, and we look forward to seeing how CRISPR/Cas9 will enhance their internal research programs and lead to more effective drugs.'
Expanding on the regional aspect of the deal, Eric added: 'Japan has one of the most developed biotechnology sectors in the world and we hope this partnership with Sumitomo Pharma is a signifier of a growing presence in this country. This represents ERS's 16th license deal in Japan.'
Financial details of the agreement are not disclosed.
Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan.
About ERS Genomics
ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology.
For additional information, please visit .
Photo - Logo -
Media contact: Dara O'Donnell [email protected] +353-1-539 0083
ERS contact: Yasuto Ando [email protected]
SOURCE ERS Genomics
MENAFN26042022003732001241ID1104093410
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.